
    
      This is a phase IIa open-label, randomized study to compare the safety, tolerability,
      pharmacokinetics (PK) and pharmacodynamics (PD) of NM-IL-12 (rHuIL-12) to standard of care in
      subjects with open surgical wounds following colostomy takedown allowed to heal by secondary
      intention.
    
  